Clinical Trial Detail

NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non Hodgkin Lymphoma & Combined With Daratumumab for Multiple Myeloma

Complete title: A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE

EXPANSION STUDY OF NKTR-255 AS A SINGLE AGENT IN RELAPSED OR

REFRACTORY HEMATOLOGICAL MALIGNANCIES AND IN COMBINATION

WITH DARATUMUMAB AS A SALVAGE REGIMEN FOR MULTIPLE MYELOMA

Research Study Number RG1005915
Principal Investigator Andrew Cowan
Phase I

Look up trial at NIH

Research Study Description

Patients will receive intravenous NKTR-255 in 21-day treatment cycles. During the Part 1 dose escalation portion of the trial, NKTR-255 will be given as monotherapy. After determination of the recommended Phase 2 dose (RP2D) of NKTR-255, approximately 18 Multiple Myeloma (MM) or non-Hodgkin lymphoma (NHL) patients who may have received a chimeric antigen receptor T-cell (CAR-T) product and had progressive disease (PD) will receive NKTR-255 and approximately 18 MM patients who previously received daratumumab or other anti-CD38 therapies will receive NKTR-255 and daratumumab.

Phase 1 study to evaluate safety and tolerability of NKTR-255 along and in combination with daratumumab in subjects with relapsed/refractory NHL and multiple myeloma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above **

Other eligibility criteria may apply.

Research Study Number RG1005915

Keywords: Multiple Myeloma (MM); Lymphoma, Non-Hodgkin (NHL)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019